Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting

- Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways

- Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Pfizer and Rilite Foundation to be presented

- Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data

- 100+ LRA- and LT-affiliated researchers presenting at ACR


News provided by

Lupus Research Alliance

Nov 07, 2019, 08:00 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, Nov. 7, 2019 /PRNewswire/ -- The Lupus Research Alliance (LRA), the largest private funder of lupus research in the world, announced today that 16 studies supported by the organization will be presented at the 2019 ACR/ARP Annual Meeting November 8-13, 2019. In addition, results of two positive clinical studies conducted by LRA's affiliate Lupus Therapeutics (LT) in collaboration with Pfizer and the Rilite Foundation focus on improving how lupus disease activity is monitored. The volume of lupus-related abstracts at the meeting includes several highly anticipated studies related to anifrolumab, obinutuzumab, ustekinumab and belimumab. 

"This meeting marks an exciting time for lupus research and of hope for the community," said LRA President and CEO Kenneth M. Farber. "The research work we have been funding and supporting is now bearing fruit, with results uncovering key insights about what causes lupus and affirming directions for potential new treatments. Also exciting, this meeting will showcase promising results of trials testing drugs that have grown out of our foundational research, bringing the very real possibility of much-needed new treatments for lupus in the offing."

Foundational Research Identifies New Pathways, Insight on Lupus Nephritis Progression

The Lupus Research Alliance has invested more than $200 million in lupus research programs through nearly 500 studies and more recently the Lupus Clinical Investigators Network (LuCIN) of 57 academic sites administered by Lupus Therapeutics. LRA-funded researchers have contributed to the identification and validation of more than 15 different disease pathways in lupus that are currently targeted by more than a dozen therapeutic approaches.

At ACR, LRA-funded investigators will be presenting novel research uncovering key insights about the various types of immune cells involved in promoting different aspects of lupus. Several presentations will focus specifically on research geared to understand how lupus affects the kidneys (lupus nephritis) -- from how the molecular profile of kidney cells change during the course of lupus nephritis to how a drug could prevent certain immune cells from entering the kidney and causing damage.

Sunday, November 10

Poster:           

The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease. Abstract #0072, Hall B5, 9:00am

Poster:           

A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis. Abstract #0641, Hall B5, 9:00am

Poster:           

Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis. Abstract #0017, Hall B5, 9:00am

Poster:           

Lyn-Deficient Murine Lupus Is Exacerbated by Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency. Abstract #0061, Hall B5, 9:00am

Monday, November 11

Poster:           

Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells. Abstract #1024, Hall B5, 9:00am

Poster:           

Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation. Abstract #1561, Hall B5, 9:00am

Oral:               

Reversible Dysregulation of Renal Circadian Rhythm in Lupus Nephritis. Abstract #1783, B403, 2:30pm

Oral:                

A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model. Abstract #1782, B403, 3:00pm

Oral:               

Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus. Abstract #1827, Sidney Marcus Auditorium, 3:15pm

Oral:               

The Glucocorticoid-Induced Protein GILZ Represent a Checkpoint in the IFN Program in SLE. Abstract #1787, Sidney Marcus Auditorium, 3:45pm

Oral:               

Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis. Abstract #1916, B405/B407, 5:00pm

Tuesday, November 12

Poster:           

Pleiotropy of Systemic LupusEerythematosus (SLE) Risk Alleles: Association with Increased Risk for Type 1 Diabetes (T1D) Complications through a PTPN22 Polymorphism. Abstract #1959, Hall B5, 9:00am

Oral:               

Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus. Abstract #2733, A302, 2:30-3:00pm

Oral:               

The Transcription Factor MAF Controls the Ability of T Peripheral Helper (Tph) Cells to Help B Cells. Abstract #2819, A311, 5:15pm           

Oral:               

Lower IL-4R in IgD+ Naïve B Cells Is a Pre-disposing Factor for Development of T-bet+ DN2 B Cells in Systemic Lupus Erythematosus. Abstract #2815, B309, 5:45pm

Wednesday, November 13

Oral:               

CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity. Abstract #2894, B304/305, 11:00am

Studies Validate Novel Assessment Tools

Lupus Therapeutics, an affiliate of LRA, focuses on accelerating testing of potential new treatments and improved ways to diagnose and monitor the effects of lupus. The organization oversees the Lupus Clinical Investigators Network (LuCIN) composed of 57 of the top research medical centers in North America. Two studies conducted through LuCIN that promise to improve disease monitoring will be presented at ACR.

Sunday, November 10

Poster:           

Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus, Abstract #662, Hall B5, 9:00-11:00am


Collaborator: Pfizer Inc

Monday, November 11

Oral:               

Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis Abstract #1919, 5:45pm, B405/B407


Collaborator: RILITE Foundation

Community Involvement Accelerates Results

LRA and LT aim to unite all sectors of the lupus community to pursue one goal – better treatments and a cure. An LRA-sponsored Patient Perspectives Poster PP07  Sunday, November 10 at 11:30 tells the lupus patient story to professionals, illustrating why their research is so urgently needed. Please visit the Lupus Research Alliance/Lupus Therapeutics BREAKING THROUGH TOGETHER Booth # 1151 (across from AbbVie #841) to learn about the many ways researchers, healthcare professionals, industry, people with lupus and family members can work collaboratively  to accelerate clinical trial participation in lupus and drug discovery.

About Lupus
Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. More than 90% of people with lupus are women; lupus most often strikes during the childbearing years of 15-45. African Americans, Latinx, Asians and Native Americans are two to three times at greater risk than Caucasians. In lupus, the immune system, which is designed to protect against infection, creates antibodies that can attack any part of the body including the kidneys, brain, heart, lungs, blood, skin, and joints. 

About the Lupus Research Alliance
The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world. The organization's stringent peer review grant process fosters diverse scientific talent who are driving discovery toward better diagnostics, improved treatments and ultimately a cure for lupus. Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

About Lupus Therapeutics
Lupus Therapeutics, an affiliate of the Lupus Research Alliance, aims to accelerate drug discovery and diagnostic innovation for all patients living with lupus. Lupus Therapeutics engages with biotechnology and pharmaceutical industry, as well as other investigators, to bring clinical trials to real people living with lupus. The organization places the patient voice at the center of strategic planning with the most creative clinicians and scientists in the world.

SOURCE Lupus Research Alliance

Related Links

http://www.lupusresearch.org

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Lupus Research Alliance Invites Communities to Walk with Us to Cure Lupus Fall Season

Lupus Research Alliance Invites Communities to Walk with Us to Cure Lupus Fall Season

Thousands of dedicated lupus champions will kick off the Lupus Research Alliance Fall Walk with Us to Cure Lupus season on Saturday, October 18 to...

Breakthrough T1D, Lupus Research Alliance, and National Multiple Sclerosis Society Award Recipients of First Common Mechanisms of Autoimmunity Insight Award

Breakthrough T1D, Lupus Research Alliance, and National Multiple Sclerosis Society Award Recipients of First Common Mechanisms of Autoimmunity Insight Award

Breakthrough T1D (formerly JDRF), the Lupus Research Alliance, and the National Multiple Sclerosis Society today announce the recipients of the...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Trade Show News

Trade Show News

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

Surveys, Polls and Research

Surveys, Polls and Research

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.